A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases

NCT00542048 | Completed Phase 2

• 1 other identifier: CT 4003
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of study CT 4003 is to assess the behavior of EndoTAG®-1 in the body (making a so-called pharmacokinetic profile). Therefore, the course of the drug in the body is examined, i.e. the amount and speed of the drug uptake as well as the distribution and the elimination of the drug is being investigated. Further objectives of the study are to assess the effect of EndoTAG®-1 on liver metastases concerning size and blood supply measured by imaging techniques (contrast-enhanced ultrasound and magnetic resonance imaging as well as duplex sonography) and to assess the effect on blood markers which are indicators for the destruction and neoplasm of blood vessels (so-called markers of angiogenesis).

Conditions

Liver Cancer; Neoplasm Metastasis

Keywords

Hepatic metastases; Angiogenesis; EndoTAG-1; Pharmacokinetics; Pharmacodynamics; Metastases of the liver

Outcome Measures

Primary Outcomes (1)

• Pharmacokinetic profile

  Last patient out

Secondary Outcomes (1)

• Tumor response, Tumor perfusion, Soluble markers of angiogenesis, Pharmacodynamics, Safety

  Last patient out

Study Arms (1)

1

EXPERIMENTAL

Drug: EndoTAG®-1

Interventions

EndoTAG®-1 DRUG

EndoTAG®-1 22 mg/m² twice weekly

1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Unresectable hepatic metastases of a carcinomatous origin with exception of HCC, biliary or bile duct carcinoma
• At least one measurable hepatic metastases \> 20 mm in diameter (measured in MRI)
• Last application of palliative chemotherapy (drug dependent on the primary tumor) at least 7 days ago
• Gender: male and female (at least 6 individuals of each gender)
• Age \>= 18 years
• Negative pregnancy test (females of childbearing potential)
• Willingness to perform double-barrier-contraception during the study and for 6 month post study medication
• ECOG performance status 0,1 or 2
• Assumed life expectancy of \> 3 month
• Signed informed consent

You may not qualify if:

• History of significant liver pathology (other than metastases, e.g. cirrhosis of the liver, PSC, PBC) or liver transplantation
• Laboratory tests (hematology, chemistry) outside specific limits:
• ANC \<= 1.0 x 10\^9/L
• Platelets \<= 100 x 10\^9/L
• Hb \<= 9.0 g/dL (\<= 5.6 mmol/L)
• Total Bilirubin \> 2.0 mg/dL
• Serum Creatinine \> 1.5 mg/dL
• Renal insufficiency with a GFR \< 60 mL/min
• Currently ongoing taxane-containing palliative chemotherapy regimen or history of taxane administration within 4 weeks prior to study entry
• Pregnancy or nursing status
• Positive HIV, HBV or HCV testing
• The patient has a contraindication for MRI or CEUS according to accepted clinical guidelines
• Known hypersensitivity to any component of the EndoTAG®-1 formulation, gadolinium-based MR-contrast media or sulphur hexafluoride
• Claustrophobia or history of active or significant neurological disorder and/or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere in the clinical and radiological evaluation of the patient during the trial
• Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study entry

Sponsors & Collaborators

• MediGene: lead

Study Sites (1)

Klinik für Internistische Onkologie in der KTB Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg

Freiburg im Breisgau, Baden-Würtemberg, 79106, Germany

Location

MeSH Terms

Conditions

Liver Neoplasms; Neoplasm Metastasis

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Liver Diseases; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Klaus Mross, PD

  Klinik für Tumorbiologie an der Albert-Ludwigs-Universität Freiburg

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 9, 2007
• First Posted: October 10, 2007
• Study Start: November 1, 2007
• Primary Completion: September 1, 2009
• Study Completion: September 1, 2009
• Last Updated: February 9, 2010

Record last verified: 2009-11

Locations

DE (1)